Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 5/20 | 0.43 |
| ▸ | HTR1D | P28221 | 4/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | AOC2 | O75106 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10850175 | 0.80 | CA2 (0.58) | CA2LMNAHTR1AHTR1D | |
| SCHEMBL11884680 | 0.79 | CA2 (0.47) | CA2HRH3HTR1AHTR1DGPBAR1 | |
| SCHEMBL1485141 | 0.79 | HRH3 (0.49) | CA2HRH3HTR1AHTR1DGPBAR1 | |
| SCHEMBL13181762 | 0.79 | HRH3 (0.46) | CA2HRH3HTR1AHTR1DGPBAR1 | |
| SCHEMBL1485140 | 0.79 | HRH3 (0.49) | CA2HRH3HTR1AHTR1DGPBAR1 | |
| SCHEMBL12095181 | 0.75 | HRH3 (0.46) | CA2HRH3HTR1AHTR1DGPBAR1 | |
| SCHEMBL8035957 | 0.74 | DRD2 (0.53) | — | |
| SCHEMBL434472 | 0.74 | SIGMAR1 (0.48) | CA2LMNAHTR1A | |
| SCHEMBL13936947 | 0.73 | GPBAR1 (0.46) | CA2HRH3HTR1AHTR1DGPBAR1 | |
| SCHEMBL17753764 | 0.73 | MTNR1A (0.65) | CA2LMNAGPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3181550-B1 | BENZOCYCLOALKENES AS ANTIFUNGAL AGENTS | BAYER IP GMBH (DE) | 2019-11-20 | — | — | EP | claimed |
| US-10093611-B2 | Benzocycloalkenes as antifungal agents | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-10-09 | — | — | US | claimed |
| EP-3181550-A1 | BENZOCYCLOALKENES AS ANTIFUNGAL AGENTS | Bayer Intellectual Property GmbH (DE) | 2017-06-21 | — | — | EP | claimed |
| US-20160023987-A1 | BENZOCYCLOALKENES AS ANTIFUNGAL AGENTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-28 | — | — | US | claimed |
| EP-2595961-A2 | BENZOCYCLOALKENES AS ANTIFUNGAL AGENTS | Bayer Intellectual Property GmbH (DE) | 2013-05-29 | — | — | EP | claimed |
| US-20130123322-A1 | BENZOCYCLOALKENES AS ANTIFUNGAL AGENTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-16 | — | — | US | claimed |
| WO-2012010579-A2 | BENZOCYCLOALKENES AS ANTIFUNGAL AGENTS | BAYER CROPSCIENCE AG (DE) | 2012-01-26 | — | — | WO | claimed |
| EP-3181550-B1 | BENZOCYCLOALKENES AS ANTIFUNGAL AGENTS | BAYER IP GMBH (DE) | 2019-11-20 | — | — | EP | disclosed |
| US-10093611-B2 | Benzocycloalkenes as antifungal agents | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-10-09 | — | — | US | disclosed |
| EP-3181550-A1 | BENZOCYCLOALKENES AS ANTIFUNGAL AGENTS | Bayer Intellectual Property GmbH (DE) | 2017-06-21 | — | — | EP | disclosed |
| US-20160023987-A1 | BENZOCYCLOALKENES AS ANTIFUNGAL AGENTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-28 | — | — | US | disclosed |
| US-9173399-B2 | Benzocycloalkenes as antifungal agents | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-03 | — | — | US | disclosed |
| EP-2595961-A2 | BENZOCYCLOALKENES AS ANTIFUNGAL AGENTS | Bayer Intellectual Property GmbH (DE) | 2013-05-29 | — | — | EP | disclosed |
| US-20130123322-A1 | BENZOCYCLOALKENES AS ANTIFUNGAL AGENTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| WO-2012010579-A2 | BENZOCYCLOALKENES AS ANTIFUNGAL AGENTS | BAYER CROPSCIENCE AG (DE) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160023987-A1 | BENZOCYCLOALKENES AS ANTIFUNGAL AGENTS | CYP51A1, ERG28, CBR1 | CA2 1375/4885HRH3 2799/4885LMNA 2084/4885 |
| US-10093611-B2 | Benzocycloalkenes as antifungal agents | CYP51A1, ERG28, CBR1 | CA2 1375/4885HRH3 2799/4885LMNA 2084/4885 |
| US-20130123322-A1 | BENZOCYCLOALKENES AS ANTIFUNGAL AGENTS | CYP51A1, ERG28, CBR1 | CA2 1375/4885HRH3 2799/4885LMNA 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.